Landscapes / Targets
PD-L1
56 drugs act on PD-L1, in 350 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs56
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Programmed death ligand-1 blocker |
Approved | 24 Nov 2026soonPhase 3 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 24 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Locally Advanced or Metastatic Urothelial Carcinoma | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Roche · Public ROG.SW |
Approved | 30 Nov 2026soonPhase 3 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer and 34 more | ||||
| Open drug page | |||||
PD-L1 antibody |
AstraZeneca · Public AZN |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Hepatocellular Carcinoma and 80 more | ||||
| Open drug page | |||||
PD-L1 antibody |
Hengrui · Public 600276.SS |
Approved in China | 30 Dec 2026Phase 2 trial completes | ||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Malignant Solid Tumors and 45 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in China | 30 Dec 2026Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor, Non-small Cell Lung Cancer and 5 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | 1 Jan 2027Phase 1 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 1 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Bristol Myers Squibb · Public BMY |
Approved | 5 Feb 2027Phase 2 trial completes | ||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Advanced Solid Tumors and 31 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in China | 1 Sep 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Cervical Cancer | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | Sep 2027Phase 2 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma and 4 more | ||||
| Open drug page | |||||
PD-L1 antibody |
CStone · Public 2616.HK |
Approved in the EU | Dec 2029Phase 3 trial completes | ||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Also tested for | Extranodal NK/T-cell Lymphoma | ||||
| Open drug page | |||||
Programmed death ligand-1 blocker |
Approved | — | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Also tested for | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and 11 more | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 2/3 | 22 Nov 2026soonPhase 2 trial completes | ||
| Next date | 22 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Advanced/Metastatic Malignant Solid Tumors and 13 more | ||||
| Open drug page | |||||
— |
Phase 3 | 24 Dec 2026Phase 2 trial completes | |||
| Next date | 24 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumour, Advanced Solid Tumor and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Malignant Tumors, Non Small Cell Lung Cancer (NSCLC) and 2 more | ||||
| Open drug page | |||||
PD-L1/VEGF-A bispecific antibody |
BioNTech +1 · Public BNTX · BMY |
Phase 3 | 1 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, SCLC and 49 more | ||||
| Open drug page | |||||
PD-L1 antibody fused to a VEGFR1 domain (PD-L1/VEGF) |
Huahai Pharmaceutical (Huaota) · Public 600521.SS |
Phase 3 | 15 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 15 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced NSCLC, Advanced Endometrial Cancer and 3 more | ||||
| Open drug page | |||||
PD-L1/4-1BB bispecific antibody |
Phase 3 | 30 Jul 2027Phase 3 trial completes | |||
| Next date | 30 Jul 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | 30 Jul 2027Phase 1/2 trial completes | ||
| Next date | 30 Jul 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Gastric or Gastroesophageal Junction Cancer, Relapsed or Advanced Non-small Cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
BL-M14D1not checked |
— |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Neuroendocrine Tumors and 20 more | ||||
| Open drug page | |||||
— |
Kelun-Biotech · Public 6990.HK |
Phase 3 | Dec 2027Phase 3 trial completes | ||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Nasopharyngeal Carcinoma, Recurrent or Metastatic and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 54 of 56 drugs. The other 2 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026